Bipolar disorder: The role of the kynurenine and melatonergic pathways

Current Pharmaceutical Design

Volumn 22, Issue 8, 2016, Pages 987-1012

  Anderson, George ^a   Jacob, Aude ^b,c   Bellivier, Frank ^b,c,d,e   Geoffroy, Pierre Alexis ^b,c,d,e  

^a CRC Scotland and London   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e FONDATION FONDAMENTAL   (France)

Author keywords

3 dioxygenase; Aryl hydrocarbon receptor; Bipolar disorder; Depression; Indoleamine 2; Inflammation; Kynurenine; Mania; Melatonin; Oxidative and nitrosative stress; Tryptophan catabolites

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MELATONIN; N ACETYLSEROTONIN; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN CATABOLITE; UNCLASSIFIED DRUG;

ADDICTION; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CIRCADIAN RHYTHM; COGNITION; COMORBIDITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLIA; HEREDITY; HERITABILITY; HUMAN; INFLAMMATION; INTESTINE; LIFE EXPECTANCY; MITOCHONDRION; NITROSATIVE STRESS; OBESITY; OXIDATIVE STRESS; PINEAL BODY; PRIORITY JOURNAL; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIPOLAR DISORDER; HUMANS; KYNURENINE; MELATONIN; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 84960117412     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151214105314     Document Type: Article

References (373)

1. Merinkangas KR, Tohen M. Epidemiology of bipolar disorder in adults and children. In: Tsuang MT, Tohen MT, Jones PB, Eds. Textbook in psychiatric epidemiology. Chichester: John Wiley and Sons 2011; pp. 329-42.
2. Leussis MP, Madison JM, Petryshen TL. Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology. Biol Mood Anxiety Disord 2012; 2(1): 18.
3. Seifuddin F, Mahon PB, Judy J, et al. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2012; 159B(5): 508-18.
4. Anderson G, Maes M. Bipolar disorder: role of immuneinflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep 2015; 17(2): 8.
5. Geoffroy PA, Etain B, Franchi JM, Bellivier F, Ritter P. Melatonin and Melatonin agonists as adjunctive treatments in Bipolar Disorders. Curr Pharm Des 2015; 21(23): 3352-8.
6. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995; 29(2): 141-52.
7. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34(4): 301-9.
8. Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66(1): 1-11.
9. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002; 17(4): 175-9.
10. Anderson G, Kubera M, Duda W, Lasó W, Berk M, Maes M. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep 2013; 65(6): 1647-54.
11. Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 2014; 18(5): 495-512.
12. Myint AM, Kim YK, Verkerk R, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007; 102(1-3): 65-72.
13. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev 2014; 45: 46-62.
14. Kim HK, Chen W, Andreazza AC. The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast 2015; 2015: 408136.
15. Duffy A, Lewitzka U, Doucette S, Andreazza A, Grof P. Biological indicators of illness risk in offspring of bipolar parents: targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry 2012; 6(2): 128-37.
16. Nievergelt CM, Kripke DF, Barrett TB, et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2006; 141B(3): 234-41.
17. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 122-8.
18. Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) 2011; 214: 89-106.
19. Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord 2013; 148(2-3): 444-8.
20. Bellivier F, Geoffroy PA, Etain B, Scott J. Sleep-and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert Opin Ther Targets 2015; 19(6): 747-63.
21. McClung CA. How might circadian rhythms control mood? Let me count the ways. Biol Psychiatry 2013; 74(4): 242-9.
22. Gama CS, Kunz M, Magalhães PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr 2013; 35(1): 70-4.
23. León-Caballero J, Pacchiarotti I, Murru A, et al. Bipolar disorder and antibodies against the N-methyl-d-aspartate receptor: A gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. Neurosci Biobehav Rev 2015; 55: 403-412.
24. Prieto ML, McElroy SL, Hayes SN, et al. Association between history of psychosis and cardiovascular disease in bipolar disorder. Bipolar Disord 2015; 17(5): 518-27.
25. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry 2015; 72(8): 757-66.
26. Geoffroy PA, Scott J, Boudebesse C, et al. Sleep in patients with remitted bipolar disorders: a meta-analysis of actigraphy studies. Acta Psychiatr Scand 2015; 131(2): 89-99.
27. Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiat Rep 2014; 16(11): 499.
28. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9(1): 11-24.
29. Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 2014; 13(5): 817-27.
30. Takahashi JS, Hong H-K, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008; 9(10): 764-75.
31. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science 1980; 210(4475): 1267-9.
32. Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 2000; 526 Pt 3: 695-702.
33. Snyder SH, Borjigin J, Sassone-Corsi P. Discovering light effects on the brain. Am J Psychiatry 2006; 163(5): 771.
34. Hickman AB, Klein DC, Dyda F. Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2. 5 A resolution suggests a catalytic mechanism. Mol Cell 1999; 3(1): 23-32.
35. do Prado CH, et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2013; 38(5): 667-76.
36. Panizzutti B, Gubert C, Schuh AL, et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker? J Affect Disord 2015; 182: 64-9.
37. Kessing LV, Vradi E, McIntyre RS, Andersen PK. Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord 2015; 180: 142-7.
38. Knijff EM, Breunis MN, van Geest MC, et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord 2006; 8(6): 740-50.
39. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25(6): 1206-13.
40. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004; 150(1-2): 116-22.
41. Torres KC, Souza BR, Miranda DM, et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 229-34.
42. Abeer, El-Sayed A, Ramy HA. Immunological changes in patients with mania: changes in cell mediated immunity in a sample from Egyptian patients. Egypt J Immunol 2006; 13(1): 79-85.
43. Munkholm K, Braüner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47(9): 1119-33.
44. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74(1): 15-25.
45. Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology 2015; 96(Pt A): 124-34.
46. Coplan JD, Gopinath S, Abdallah CG, Berry BR. A neurobiological hypothesis of treatment-resistant depression-mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci 2014; 8: 189.
47. Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci 2013; 263: 159-65.
48. Barbosa IG, Rocha NP, de Miranda AS, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res 2012; 46: 389-393.
49. Soeiro-de-Souza MG, Gold PW, Brunoni AR, et al. Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci Lett 2014; 564: 111-4.
50. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013; 150(2): 456-9.
51. Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. Creactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry 2015; 76(2): 142-50.
52. Hsuchou H, Kastin AJ, Mishra PK, Pan W. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem 2012; 30(5): 1109-19.
53. Patel JP, Frey BN. Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder? Neural Plast 2015; 2015: 708306.
54. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011; 76: 54-60.
55. Hercher C, Chopra V, Beasley CL. Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. J Psychiatry Neurosci 2014; 39(6): 376-85.
56. Hope S, Ueland T, Steen NE, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013; 145(1-3): 36-42.
57. Remlinger-Molenda A, Wójciak P, Michalak M, Rybakowski J. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol 2012; 46(4): 599-611.
58. Hsu JW, Lirng JF, Wang SJ, et al. Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study. Bipolar Disord 2014; 16(3): 241-8.
59. Anderson G, Ojala J. Alzheimer's and seizures: interleukin-18, indoleamine 2, 3-dioxygenase and quinolinic Acid. Int J Tryptophan Res 2010; 3: 169-73.
60. Liu YN, Peng YL, Liu L, et al. TNFα mediates stress-induced depression by upregulating indoleamine 2, 3-dioxygenase in a mouse model of unpredictable chronic mild stress. Eur Cytokine Netw 2015; 26(1): 15-25.
61. Cetin T, Guloksuz S, Cetin EA, et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry 2012; 12: 158.
62. Becking K, Boschloo L, Vogelzangs N, et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry 2013; 3: e314.
63. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116(3): 214-7.
64. Ortiz-Domínguez A, Hernández ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9(6): 596-602.
65. Bai YM, Su TP, Tsai SJ, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187-92.
66. Wieck A, Grassi-Oliveira R, do Prado CH, et al. Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: Differential reactivity in bipolar disorder. Neurosci Lett 2014; 580: 17-21.
67. Barbosa IG, Morato IB, de Miranda AS, Bauer ME, Soares JC, Teixeira AL. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord 2014; 157: 41-4.
68. Fries GR, Vasconcelos-Moreno MP, Gubert C, et al. Hypothalamic-pituitary-adrenal axis dysfunction and illness progression in bipolar disorder. Int J Neuropsychopharmacol 2014; 18(1).
69. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007; 9(7): 743-53.
70. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104(1-3): 91-5.
71. Nassar A, Azab AN. Effects of Lithium on Inflammation. ACS Chem Neurosci 2014; 5(6): 451-8.
72. Goldstein BI, Collinger KA, Lotrich F, et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Ch Adol Psychopharmacol 2011; 21: 479-484.
73. Asami T, Ito T, Fukumitsu H, Nomoto H, Furukawa Y, Furukawa S. Autocrine activation of cultured macrophages by brain-derived neurotrophic factor. Biochem Biophys Res Commun 2006; 344(3): 941-7.
74. Linker RA, Lee DH, Flach AC, et al. Thymocyte-derived BDNF influences T-cell maturation at the DN3/DN4 transition stage. Eur J Immunol 2015; 45(5): 1326-38.
75. Brambilla P, Bellani M, Isola M, et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry 2014; 4: e406.
76. Muxel SM, Pires-Lapa MA, Monteiro AW, et al. NF-kB Drives the Synthesis of Melatonin in RAW 264. 7 Macrophages by Inducing the Transcription of the Arylalkylamine-Nacetyltransferase (AANAT) Gene. PLoS One 2012; 7(12): e52010.
77. Markus RP, Cecon E, Pires-Lapa MA. Immune-pineal axis: nuclear factor +B (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci 2013; 14(6): 10979-97.
78. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. J Pineal Res 2007; 43(4): 365-71.
79. Alloy LB, Nusslock R, Boland EM. The development and course of bipolar spectrum disorders: an integrated reward and circadian rhythm dysregulation model. Annu Rev Clin Psychol 2015; 11: 213-50.
80. Barbosa IG, Nogueira CR, Rocha NP, et al. Altered intracellular signaling cascades in peripheral blood mononuclear cells from BD patients. J Psychiatr Res 2013; 47(12): 1949-54.
81. Bartels M, van Solinge WW, den Breeijen HJ, Bierings MB, Coffer PJ, Egberts TC. Valproic acid treatment is associated with altered leukocyte subset development. J Clin Psychopharmacol 2012; 32(6): 832-4.
82. Himmerich H, Bartsch S, Hamer H, et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3-and anti-Cd40-stimulated blood in vitro. Oxid Med Cell Longev 2014; 2014: 806162.
83. Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol 2012; 15(9): 1343-50.
84. Rolstad S, Jakobsson J, Sellgren C, et al. CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. Eur Neuropsychopharmacol 2015; 25(8): 1091-8.
85. Rolstad S, Jakobsson J, Sellgren C, et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PLoS One 2015; 10(5): e0127100.
86. Jakobsson J, Bjerke M, Sahebi S, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 2015; 40(4): 250-8.
87. Jakobsson J, Bjerke M, Ekman CJ, et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology 2014; 39(10): 2349-56.
88. Jakobsson J, Bjerke M, Ekman CJ, et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatr Res 2014 Jul 30; 217(3): 143-6.
89. Valvassori SS, Tonin PT, Varela RB, et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disord 2015; 17(5): 507-17.
90. Söderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci 2011; 36(2): 114-8.
91. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16(7): 751-62.
92. de Sousa RT, Machado-Vieira R, Zarate CA Jr, Manji HK. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets 2014; 18(10): 1131-47.
93. Bahna SG, Sathiyapalan A, Foster JA, Niles LP. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer's disease. Neurosci Lett 2014; 576: 84-7.
94. Behram Kandemir Y, Sarikcioglu L. Melatonin and its therapeutic actions on peripheral nerve regeneration. Folia Morphol (Warsz) 2015; 74(3): 283-9.
95. Gaécki P, Talarowska M, Anderson G, Berk M, Maes M. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Med Sci Monit 2015; 21: 1535-47.
96. Shi K, Wang F, Jiang H, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59(9): 2109-17.
97. Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF 3rd, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014; 29(6): 635-44.
98. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, et al. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 2013; 28(2): 160-7.
99. Volkert J, Kopf J, Kazmaier J, et al. Evidence for cognitive subgroups in bipolar disorder and the influence of subclinical depression and sleep disturbances. Eur Neuropsychopharmacol 2015; 25(2): 192-202.
100. Shin HY, Han HJ, Shin DJ, Park HM, Lee YB, Park KH. Sleep problems associated with behavioral and psychological symptoms as well as cognitive functions in Alzheimer's disease. J Clin Neurol 2014; 10(3): 203-9.
101. Buoli M, Caldiroli A, Caletti E, Zugno E, Altamura AC. The impact of mood episodes and duration of illness on cognition in bipolar disorder. Compr Psychiatry 2014; 55(7): 1561-6.
102. Rosa AR, Magalhães PV, Czepielewski L, et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry 2014; 75(5): e450-6.
103. Permoda-Osip A, Dorszewska J, Skibinska M, Chlopocka-Wozniak M, Rybakowski JK. Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates. Neuropsychobiology 2013; 68(4): 193-6.
104. Murawska-Cialowicz E, Januszewska L, Zuwala-Jagiello J, et al. Melatonin decreases homocysteine level in blood of rats. J Physiol Pharmacol 2008; 59(4): 717-29.
105. Axelrod J, Weissbach H. Enzymatic O-methylation of Nacetylserotonin to melatonin. Science 1960; 131(3409): 1312.
106. McElroy SL, Kemp DE, Friedman ES, et al. Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatr Scand; In press.
107. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med 2011; 13(2): 93-116.
108. Boudebesse C, Geoffroy PA, Henry C, et al. Links between sleep and body mass index in bipolar disorders: an exploratory study. Eur Psychiatry 2015; 30(1): 89-93.
109. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord 2015; 17(1): 39-49.
110. Stich O, Andres TA, Gross CM, Gerber SI, Rauer S, Langosch JM. An observational study of inflammation in the central nervous system in patients with bipolar disorder. Bipolar Disord 2015; 17(3): 291-302.
111. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008; 29(1): 117-24.
112. Anderson G, Maes M. The Gut-Brain Axis: The Role of Melatonin in Linking Psychiatric, Inflammatory and Neurodegenerative Conditions. Adv Integr Med 2015; 2(1): 31-37.
113. Lucas K, Morris G, Anderson G, Maes M. The Toll-like Receptor Radical Cycle pathway: a new drug target in immune-related chronic fatigue. Curr Psychiatry Rep 2015; 17(2): 8.
114. Sommansson A, Nylander O, Sjöblom M. Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo. J Pineal Res 2013; 54(3): 282-91.
115. Tunçel ÖK, Sarśoy G, Bilgici B, et al. Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res 2015; 228(3): 688-94.
116. Anderson G, Maes M. Oxidative/nitrosative stress and immunoinflammatory pathways in depression: treatment implications. Curr Pharm Des 2014; 20(23): 3812-47.
117. Aydemir O, Çubukçuólu Z, Erdin S, Tać C, Onur E, Berk M. Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr 2014; 36(4): 293-7.
118. Selek S, Altindag A, Saracoglu G, Aksoy N. Oxidative markers of Myeloperoxidase and Catalase and their diagnostic performance in bipolar disorder. J Affect Disord 2015; 181: 92-5.
119. Oliveira J, Debnath M, Etain B, et al. Violent suicidal behaviour in bipolar disorder is associated with nitric oxide synthase 3 gene polymorphism. Acta Psychiatr Scand 2015; 132(3): 218-25.
120. Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 2015; 131(6): 417-25.
121. Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 2013; 127(4): 552-61.
122. Versace A, Andreazza AC, Young LT, et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014; 19(2): 200-8.
123. Bortolasci CC, Vargas HO, Souza-Nogueira A, et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 2014; 159: 23-30.
124. Chitty KM, Lagopoulos J, Hickie IB, Hermens DF. A longitudinal proton magnetic resonance spectroscopy study investigating oxidative stress as a result of alcohol and tobacco use in youth with bipolar disorder. J Affect Disord 2015; 175: 481-7.
125. Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37(1): 56-61.
126. Khairova R, Pawar R, Salvadore G, et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 2012; 5(3): 680-2.
127. Albayrak A, Halici Z, Polat B, et al. Protective effects of lithium: a new look at an old drug with potential antioxidative and antiinflammatory effects in an animal model of sepsis. Int Immunopharmacol 2013; 16(1): 35-40.
128. Wilson CB, McLaughlin LD, Ebenezer PJ, Nair AR, Francis J. Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder. Behav Brain Res 2014; 268: 72-80.
129. Valvassori SS, Resende WR, Lopes-Borges J, et al. Effects of mood stabilizers on oxidative stress-induced cell death signaling pathways in the brains of rats subjected to the ouabain-induced animal model of mania: Mood stabilizers exert protective effects against ouabain-induced activation of the cell death pathway. J Psychiatr Res 2015; 65: 63-70.
130. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 2013; 16(7): 1505-12.
131. Abe N, Uchida S, Otsuki K, et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res 2011; 45(8): 1106-12.
132. Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45(8): 995-1004.
133. Iuvone PM, Boatright JH, Tosini G, Ye K. N-acetylserotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain. Adv Exp Med Biol 2014; 801: 765-71.
134. Anderson G, Maes M. Metabolic syndrome, Alzheimer's, schizophrenia and depression: role for leptin, melatonin, kynurenine pathways and neuropeptides. Chap 13. In: Farooqui T, Farooqui AA, Eds. Metabolic syndrome and neurological disorders. Chichester, UK: John Wiley & Sons Ltd 2013.
135. Hatch J, Andreazza A, Olowoyeye O, Rezin GT, Moody A, Goldstein BI. Cardiovascular and psychiatric characteristics associated with oxidative stress markers among adolescents with bipolar disorder. J Psychosom Res 2015; 79(3): 222-7.
136. Anderson G, Maes M. Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala. Curr Neuropharmacol 2014; 12(2): 148-67.
137. Anderson G, Maes M. Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol Neurobiol 2014; 49(2): 771-83.
138. Anderson G, Rodriguez M. Multiple sclerosis: the role of melatonin and N-acetylserotonin. Mult Scler Relat Disord 2015; 4(2): 112-23.
139. Anderson G, Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 101-14.
140. Wang P, Sun X, Wang N, Tan DX, Ma F. Melatonin enhances the occurrence of autophagy induced by oxidative stress in Arabidopsis seedlings. J Pineal Res 2015; 58(4): 479-89.
141. Teng YC, Tai YI, Huang HJ, Lin AM. Melatonin ameliorates arsenite-induced neurotoxicity: involvement of autophagy and mitochondria. Mol Neurobiol 2015; 52(2): 1015-22.
142. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18: R169-76.
143. Li CT, Bai YM, Hsieh JC, et al. Peripheral and central glucose utilizations modulated by mitochondrial DNA 10398A in bipolar disorder. Psychoneuroendocrinology 2015; 55: 72-80.
144. Xiao Y, Zhang J, Wang Y, et al. Limited association between Disrupted in Schizophrenia 1 (DISC1) gene and bipolar disorder in the Chinese population. Psychiatr Genet 2011; 21(1): 42-6.
145. Ogawa F, Malavasi EL, Crummie DK, et al. DISC1 complexes with TRAK1 and Miro1 to modulate anterograde axonal mitochondrial trafficking. Hum Mol Genet 2014; 23(4): 906-19.
146. Lee H, Kang E, GoodSmith D, et al. DISC1-mediated dysregulation of adult hippocampal neurogenesis in rats. Front Syst Neurosci 2015; 9: 93.
147. Anderson G, Maes M. Reconceptualizing adult neurogenesis: role for sphingosine-1-phosphate and fibroblast growth factor-1 in coordinating astrocyte-neuronal precursor interactions. CNS Neurol Disord Drug Targets 2014; 13(1): 126-36.
148. Wang JF. Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psychiatry 2007; 52: 753-762.
149. Sitarz KS, Elliott HR, Karaman BS, Relton C, Chinnery PF, Horvath R. Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. Mol Genet Metab 2014; 112(1): 57-63.
150. Chang CC, Jou SH, Lin TT, Liu CS. Mitochondrial DNA variation and increased oxidative damage in euthymic patients with bipolar disorder. Psychiatry Clin Neurosci 2014; 68(7): 551-7.
151. Toker L, Agam G. Lithium, inositol and mitochondria. ACS Chem Neurosci 2014; 5(6): 411-2.
152. Colasanti A, Owen DR, Grozeva D, et al. Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18 kDa Translocator Protein (TSPO). Psychoneuroendocrinology 2013; 38(11): 2826-9.
153. Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 2006; 281(30): 21512-25.
154. Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 1993; 612(1-2): 221-30.
155. Ghadiri M, Nourmohammadi I, Fasihi Ramandi M, Moazen Zadeh E. Association involving serotonin transporter gene linked polymorphic region and bipolar disorder type 1 in Iranian population. Asia Pac Psychiatry; In press.
156. Benedetti F, Bollettini I, Poletti S, et al. White matter microstructure in bipolar disorder is influenced by the serotonin transporter gene polymorphism 5-HTTLPR. Genes Brain Behav 2015; 14(3): 238-50.
157. Frye MA, McElroy SL, Prieto ML, et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressantinduced mania. J Clin Psychiatry 2015; 76(2): 174-80.
158. Benedetti F, Riccaboni R, Poletti S, et al. The serotonin transporter genotype modulates the relationship between early stress and adult suicidality in bipolar disorder. Bipolar Disord 2014; 16(8): 857-66.
159. Chen S, Huang X, Yu T, et al. Association study of TPH2 polymorphisms and bipolar disorder in the Han Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 97-100.
160. Anderson G, Maes M, Berk M. Inflammation-related disorders in the tryptophan catabolite (TRYCAT) pathway in depression and somatization. Adv Prot Chem Struct Biol 2012; 88: 27-48.
161. Ren S, Correia MA. Heme: a regulator of rat hepatic tryptophan 2, 3-dioxygenase? Arch Biochem Biophys 2000; 377(1): 195-203.
162. Blanco Ayala T, Lugo Huitrón R, Carmona Aparicio L, et al. Alternative kynurenic acid synthesis routes studied in the rat cerebellum. Front Cell Neurosci 2015; 9: 178.
163. Olsson SK, Samuelsson M, Saetre P, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010; 35(3): 195-9.
164. Walling D, Marder SR, Kane J, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull; In press.
165. Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther 2010; 126(3): 251-62.
166. Deutsch SI, Burket JA, Benson AD. Targeting the +7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down's syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54: 131-9.
167. Ancín I, Cabranes JA, Santos JL, et al. CHRNA7 haplotypes are associated with impaired attention in euthymic bipolar disorder. J Affect Disord 2011; 133(1-2): 340-5.
168. Joo EJ, Lee KY, Kim HS, Kim SH, Ahn YM, Kim YS. Genetic Association Study of the Alpha 7 Nicotinic Receptor (CHRNA7) with the Development of Schizophrenia and Bipolar Disorder in Korean Population. Psychiatry Investig 2010; 7(3): 196-201.
169. Mishra NC, Rir-sima-ah J, Boyd RT, et al. Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha9/alpha 10-nicotinic receptors. J Immunol 2010; 185(1): 588-96.
170. Suzuki T, Hide I, Matsubara A, et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006; 83(8): 1461-70.
171. Wang Y, Zhu N, Wang K, Zhang Z, Wang Y. Identification of +7 nicotinic acetylcholine receptor on hippocampal astrocytes cultured in vitro and its role on inflammatory mediator secretion. Neural Regen Res 2012; 7(22): 1709-14.
172. Parada E, Buendia I, León R, et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. J Pineal Res 2014; 56(2): 204-12.
173. Jeong JK, Park SY. Melatonin regulates the autophagic flux via activation of alpha-7 nicotinic acetylcholine receptors. J Pineal Res 2015; 59(1): 24-37.
174. Kanai M, Funakoshi H, Takahashi H, et al. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2009; 2: 8.
175. Kopka K, Riemann B, Friedrich M, et al. Characterization of 3-[(123)I]iodo-L-alpha-methyl tyrosine transport in astrocytes of neonatal rats. J Neurochem 2001; 76(1): 97-104.
176. Zunszain PA, Anacker C, Cattaneo A, et al. Interleukin-1B: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012; 37(4): 939-49.
177. Savitz J, Dantzer R, Wurfel BE, et al. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology 2015; 52: 200-11.
178. Johansson AS, Owe-Larsson B, Asp L, et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res 2013; 47(11): 1815-23.
179. Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry 2014; 19(3): 334-41.
180. Reininghaus EZ, McIntyre RS, Reininghaus B, et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord 2014; 16(4): 432-40.
181. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eightweek randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014; 16(4): 410-21.
182. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012; 27(2): 113-9.
183. Stubbs B, Eggermont L, Mitchell AJ, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale metaanalysis. Acta Psychiatr Scand 2015; 131(2): 75-88.
184. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196(2-3): 243-9.
185. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand 2014; 129(2): 83-97.
186. Hackel D, Pflücke D, Neumann A, et al. The connection of monocytes and reactive oxygen species in pain. PLoS One 2013; 8(5): e63564.
187. Tsuji N, Fukuda K, Nagata Y, et al. The activation mechanism of the aryl hydrocarbon receptor (AhR) by molecular chaperone HSP90. FEBS Open Bio 2014; 4: 796-803.
188. Shen WW, Liu HC, Yang YY, et al. Anti-heat shock protein 90 is increased in acute mania. Aust N Z J Psychiatry 2006; 40(8): 712-6.
189. Anderson G, Beischlag TV, Vinciguerra M, Mazzoccoli G. The circadian clock circuitry and the AHR signaling pathway in physiology and pathology. Biochem Pharmacol 2013; 85(10): 1405-16.
190. Geoffroy PA, Etain B, Sportiche S, Bellivier F. Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response. Int J Bipolar Disord 2014; 2(1): 28.
191. Schubert KO, Föcking M, Cotter DR. Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: Potential roles in GABAergic interneuron pathology. Schizophr Res 2015; 167(1-3): 64-72.
192. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 2014; 32: 403-32.
193. Burris HH, Baccarelli AA, Byun HM, et al. Offspring DNA methylation of the aryl-hydrocarbon receptor repressor gene is associated with maternal BMI, gestational age, and birth weight. Epigenetics 2015: 1-9.
194. Chudal R, Sourander A, Polo-Kantola P, et al. Perinatal factors and the risk of bipolar disorder in Finland. J Affect Disord 2014; 155: 75-80.
195. Canetta SE, Bao Y, Co MD, et al. Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring. Am J Psychiatry 2014; 171(5): 557-63.
196. Talati A, Bao Y, Kaufman J, Shen L, Schaefer CA, Brown AS. Maternal smoking during pregnancy and bipolar disorder in offspring. Am J Psychiatry 2013; 170(10): 1178-85.
197. Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type1regulatory Tcells induced by IL-27. Nat Immunol 2010; 11: 854-61.
198. De Abrew KN, Phadnis AS, Crawford RB, Kaminski NE, Thomas RS. Regulation of Bach2 by the aryl hydrocarbon receptor as a mechanism for suppression of B-celldifferentiation by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2011; 252: 150-8.
199. Wang Y, Yang BH, Li H, Cao S, Ren XB, Yu JP. IDOβ DCs and signalling pathways. Curr Cancer Drug Targets 2013; 13(3): 278-88.
200. Kong E, Sucic S, Monje FJ, et al. STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior. Sci Rep 2015; 5: 9009.
201. Wang H, Wei Y, Yu D. Control of lymphocyte homeostasis and effector function by the aryl hydrocarbon receptor. Int Immunopharmacol 2015; 28(2): 818-24.
202. Filbrandt CR, Wu Z, Zlokovic B, Opanashuk L, Gasiewicz TA. Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes. Neurotoxicology 2004; 25(4): 605-16.
203. Xu G, Li Y, Yoshimoto K, et al. 2, 3, 7, 8-Tetrachlorodibenzo-pdioxin stimulates proliferation of HAPI microglia by affecting the Akt/GSK-3+/cyclin D1 signaling pathway. Toxicol Lett 2014; 224(3): 362-70.
204. Dutheil F, Dauchy S, Diry M, et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009; 37(7): 1528-38.
205. Lee YH, Lin CH, Hsu PC, et al. Aryl hydrocarbon receptor mediates both proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated microglia. Glia 2015; 63(7): 1138-54.
206. Dever DP, Adham ZO, Thompson B, et al. Aryl hydrocarbon receptor (AhR) deletion in cerebellar granule neuron precursors impairs neurogenesis. Dev Neurobiol; In press.
207. Johnson CP, Follmer RL, Oguz I, et al. Brain abnormalities in bipolar disorder detected by quantitative T1+ mapping. Mol Psychiatry 2015; 20(2): 201-6.
208. Rasinger JD, Carroll TS, Lundebye AK, Hogstrand C. Cross-omics gene and protein expression profiling in juvenile female mice highlights disruption of calcium and zinc signalling in the brain following dietary exposure to CB-153, BDE-47, HBCD or TCDD. Toxicology 2014; 321: 1-12.
209. García-Lara L, Pérez-Severiano F, González-Esquivel D, Elizondo G, Segovia J. Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress. J Neurosci Res 2015; 93(9): 1423-33.
210. Weber MD, Frank MG, Tracey KJ, Watkins LR, Maier SF. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J Neurosci 2015; 35(1): 316-24.
211. Frank MG, Weber MD, Watkins LR, Maier SF. Stress sounds the alarmin: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. Brain Behav Immun 2015; 48: 1-7.
212. Aluru N, Vijayan MM. Aryl hydrocarbon receptor activation impairs cortisol response to stress in rainbow trout by disrupting the rate-limiting steps in steroidogenesis. Endocrinology 2006; 147(4): 1895-903.
213. Frank MG, Hershman SA, Weber MD, Watkins LR, Maier SF. Chronic exposure to exogenous glucocorticoids primes microglia to pro-inflammatory stimuli and induces NLRP3 mRNA in the hippocampus. Psychoneuroendocrinology 2014; 40: 191-200.
214. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008; 105(28): 9721-6.
215. Bruhs A, Haarmann-Stemmann T, Frauenstein K, Krutmann J, Schwarz T, Schwarz A. Activation of the arylhydrocarbon receptor causes immunosuppression primarily by modulating dendritic cells. J Invest Dermatol 2015; 135(2): 435-44.
216. León-Caballero J, Pacchiarotti I, Murru A, et al. Bipolar disorder and antibodies against the N-methyl-d-aspartate receptor: A gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. Neurosci Biobehav Rev 2015; 55: 403-12.
217. Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand 2015; 132(3): 180-91.
218. Degner D, Haust M, Meller J, Rüther E, Reulbach U. Association between autoimmune thyroiditis and depressive disorder in psychiatric outpatients. Eur Arch Psychiatry Clin Neurosci 2015; 265(1): 67-72.
219. Hayes MD, Ovcinnikovs V, Smith AG, Kimber I, Dearman RJ. The aryl hydrocarbon receptor: differential contribution to T helper 17 and T cytotoxic 17 cell development. PloS One 2014; 9(9): e106955.
220. Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B. Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PloS One. 2013; 8: e79819.
221. Chinen I, Nakahama T, Kimura A, et al. The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. Int Immunol 2015; 27(8): 405-15.
222. Mohinta S, Kannan AK, Gowda K, Amin SG, Perdew GH, August A. Differential regulation of Th17 and T regulatory cell differentiation by aryl hydrocarbon receptor dependent xenobiotic response element dependent and independent pathways. Toxicol Sci 2015; 145(2): 233-43.
223. Lee JH, Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev 2010; 34: 426-44.
224. Hubbard TD, Murray IA, Bisson WH, et al. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci Rep 2015; 5: 12689.
225. Bansal T, Alaniz RC, Wood TK, Jayaraman A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci USA 2010; 107: 228-33.
226. Fukumoto S, Toshimitsu T, Matsuoka S, et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol Cell Biol 2014; 92(5): 460-5.
227. Carreira VS, Fan Y, Wang Q, et al. Ah receptor signaling controls the expression of cardiac development and homeostasis genes. Toxicol Sci 2015; 147(2): 425-35.
228. Goldstein BI, Schaffer A, Wang S, Blanco C. Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. J Clin Psychiatry 2015; 76(2): 163-9.
229. Zhang L, Hatzakis E, Nichols RG, et al. Metabolomics reveals that aryl hydrocarbon receptor activation by environmental chemicals induces systemic metabolic dysfunction in mice. Environ Sci Technol 2015; 49(13): 8067-77.
230. McNamara RK, Rider T, Jandacek R, Tso P. Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis. Psychiatry Res 2014; 215(3): 560-7.
231. Hunter JE, Zhang J, Kris-Etherton PM. Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. Am J Clin Nutr 2010; 91(1): 46-63.
232. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9(4): e94112.
233. Xu CX, Wang C, Zhang ZM, et al. Aryl hydrocarbon receptor deficiency protects mice from diet-induced adiposity and metabolic disorders through increased energy expenditure. Int J Obes (Lond) 2015; 39(8): 1300-9.
234. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009; 150(12): 5311-7.
235. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eightweek randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014; 16(4): 410-21.
236. McMillan BJ, McMillan SN, Glover E, Bradfield CA. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin induces premature activation of the KLF2 regulon during thymocyte development. J Biol Chem 2007; 282(17): 12590-7.
237. Ichii O, Otsuka-Kanazawa S, Nakamura T, et al. Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS One 2014; 9(9): e108448.
238. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005; 19(12): 1646-56.
239. Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med 2015; 21(6): 354-63.
240. Weichand B, Weis N, Weigert A, Grossmann N, Levkau B, Brüne B. Apoptotic cells enhance sphingosine-1-phosphate receptor 1 dependent macrophage migration. Eur J Immunol 2013; 43(12): 3306-13.
241. Eskan MA, Rosem BG, Benakanakere MR. TLR4 and S1P receptors cooperate to enhance inflammatory cytokine production in human gingival epithelial cells. Eur J Immunol 2008; 38(4): 1138-47.
242. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008; 102(8): 950-958.
243. Wada T, Sunaga H, Ohkawara R, Shimba S. Aryl hydrocarbon receptor modulates NADPH oxidase activity via direct transcriptional regulation of p40phox expression. Mol Pharmacol 2013; 83(5): 1133-40.
244. He M, Zhang B, Wei X, et al. HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J Cell Mol Med 2013; 17(4): 531-42.
245. Mohammad G, Alam K, Nawaz MI, Siddiquei MM, Mousa A, Abu El-Asrar AM. Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers. J Physiol Biochem 2015; 71(3): 359-72.
246. Chang CC, Sue YM, Yang NJ, Lee YH, Juan SH. 3-Methylcholanthrene, an AhR agonist, caused cell-cycle arrest by histone deacetylation through a RhoA-dependent recruitment of HDAC1 and pRb2 to E2F1 complex. PLoS One 2014; 9(3): e92793.
247. Chang CC, Lee PS, Chou Y, Hwang LL, Juan SH. Mediating effects of aryl-hydrocarbon receptor and RhoA in altering brain vascular integrity: the therapeutic potential of statins. Am J Pathol 2012; 181(1): 211-21.
248. Chang TK, Chen J, Yang G, Yeung EY. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J Pineal Res 2010; 48(1): 55-64.
249. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005; 33(4): 489-94.
250. Yi L, Luo JF, Xie BB, et al. +7 Nicotinic acetylcholine receptor is a novel mediator of sinomenine anti-inflammation effect in macrophages stimulated by lipopolysaccharide. Shock 2015; 44(2): 188-95.
251. Kennedy SH, Tighe S, McVey G, Brown GM. Melatonin and cortisol «switches» during mania, depression, and euthymia in a drugfree bipolar patient. J Nerv Ment Dis 1989; 177(5): 300-3.
252. Nováková M, Práko J, Látalová K, Sládek M, Sumová A. The circadian system of patients with bipolar disorder differs in episodes of mania and depression. Bipolar Disord 2015; 17(3): 303-14.
253. Nurnberger JI Jr, Adkins S, Lahiri DK, et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 2000; 57(6): 572-9.
254. Nurnberger JI Jr, Berrettini W, Tamarkin L, Hamovit J, Norton J, Gershon E. Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 1988; 1(3): 217-23.
255. Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996; 63(2-3): 219-22.
256. McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Human melatonin suppression by light is intensity dependent. J Pineal Res 1989; 6(2): 149-56.
257. Hallam KT, Olver JS, Chambers V, Begg DP, McGrath C, Norman TR. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006; 31(7): 867-75.
258. Lam RW, Berkowitz AL, Berga SL, Clark CM, Kripke DF, Gillin JC. Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res 1990; 33(2): 129-34.
259. Whalley LJ, Perini T, Shering A, Bennie J. Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res1991; 38(1): 13-9.
260. Bellivier F, Geoffroy P-A, Etain B, Scott J. Sleep-and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert Opin Ther Targets 2015; 1-17.
261. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001; 22(1): 18-32.
262. Hallam KT, Olver JS, Norman TR. Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers. Neuropsychopharmacol 2005; 30(7): 1400-4.
263. Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. Int J Neuropsychopharmacol 2005; 8(2): 255-9.
264. Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11(2-3): 325-34.
265. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PloS One 2013; 8(5): e63773.
266. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A metaanalysis. J Gen Intern Med 2005; 20(12): 1151-8.
267. van Geijlswijk IM, Korzilius HPLM, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010; 33(12): 1605-14.
268. Robillard R, Naismith SL, Rogers NL, et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. J Affect Disord 2013; 145(2): 260-3.
269. Sarrazin S, Etain B, Vederine F-E, et al. MRI exploration of pineal volume in bipolar disorder. J Affect Disord 2011; 135(1-3): 377-9.
270. Fındıklı E, Inci MF, Gökçe M, Fındıklı HA, Altun H, Karaaslan MF. Pineal gland volume in schizophrenia and mood disorders. Psychiatr Danub 2015; 27(2): 153-8.
271. Milhiet V, Boudebesse C, Bellivier F, et al. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front Biosci Sch Ed 2014; 6: 120-37.
272. Kennedy JS, Gwirtsman HE, Schmidt DE, et al. Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sci 2002; 71(14): 1703-15.
273. Valevski A, Modai I, Jerushalmy Z, Kikinzon L, Weizman A. Effect of melatonin on active transport of serotonin into blood platelets. Psychiatry Res 1995; 57(2): 193-6.
274. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol Adv Ophthalmol 2004; 108(1): 17-40.
275. Yocca FD, de Paul Lynch V, Friedman E. Effect of chronic lithium treatment on rat pineal rhythms: N-acetyltransferase, Nacetylserotonin and melatonin. J Pharmacol Exp Ther 1983; 226(3): 733-7.
276. Haque R, Alonso-Gómez AL, Chaurasia SS, Iuvone PM. Diurnal regulation of arylalkylamine N-acetyltransferase activity in chicken retinal cells in vitro: analysis of culture conditions. Mol Vis 2003; 9: 52-9.
277. Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21(18): 4030-7.
278. Geoffroy PA, Boudebesse C, Henrion A, et al. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes Brain Behav 2014; 13(3): 299-304.
279. Söderquist F, Hellström PM, Cunningham JL. Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. PLoS One 2015; 10(3): e0120195.
280. Liu YJ, Zhuang J, Zhu HY, Shen YX, Tan ZL, Zhou JN. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res 2007; 43(3): 232-8.
281. Pack W, Hill DD, Wong KY. Melatonin modulates M4-type ganglion-cell photoreceptors. Neuroscience 2015; 303: 178-88.
282. Liu YJ, Meng FT, Wu L, Zhou JN. Serotoninergic and melatoninergic systems are expressed in mouse embryonic fibroblasts NIH3T3 cells. Neuro Endocrinol Lett 2013; 34(3): 236-40.
283. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res 2013; 54(2): 127-38.
284. Kong PJ, Byun JS, Lim SY, et al. Melatonin Induces Akt Phosphorylation through Melatonin Receptor-and PI3K-Dependent Pathways in Primary Astrocytes. Korean J Physiol Pharmacol 2008; 12(2): 37-41.
285. Tocharus J, Khonthun C, Chongthammakun S, Govitrapong P. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J Pineal Res 2010; 48(4): 347-52.
286. Lardone PJ, Carrillo-Vico A, Naranjo MC, et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 2006; 206(1): 273-9.
287. Anderson G, Berk M, Dean O, Moylan S, Maes M. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 2014; 28(1): 1-10.
288. Sommansson A, Saudi WS, Nylander O, Sjöblom M. Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J Physiol Gastrointest Liver Physiol 2013; 305(1): G95-G105.
289. Ortiz F, Acuña-Castroviejo D, Doerrier C, et al. Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis. J Pineal Res 2015; 58(1): 34-49.
290. Jang SW, Liu X, Pradoldej S, et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci USA 2010; 107(8): 3876-81.
291. Inal-Emiroglu FN, Karabay N, Resmi H, et al. Correlations between amygdala volumes and serum levels of BDNF and NGF as a neurobiological markerin adolescents with bipolar disorder. J Affect Disord 2015 Aug 15; 182: 50-6.
292. Lauxen Peruzzolo T, Anes M, Kohmann Ade M, et al. Correlation between peripheral levels of brain-derived neurotrophic factor and hippocampal volume in children and adolescents with bipolar disorder. Neural Plast 2015; 2015: 324825.
293. Carter MD, Calcutt MW, Malow BA, Rose KL, Hachey DL. Quantitation of melatonin and n-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS. J Mass Spectrom 2012; 47(3): 277-85.
294. Yao JK, Dougherty GG Jr, Reddy RD, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15(9): 938-53.
295. Fries GR, Valvassori SS, Bock H, et al. Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania. J Psychiatr Res 2015; 68: 329-36.
296. Härtter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21(2): 167-74.
297. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005; 33(4): 489-94.
298. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56(2): 123-7.
299. Niitsu T, Fabbri C, Serretti A. Predictors of switch from depression to mania in bipolar disorder. J Psychiatr Res 2015; 66-67: 45-53.
300. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161(9): 1537-1547.
301. Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3(5): 259-265.
302. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63(6): 508-512.
303. Eppel AB. Antidepressants in the treatment of bipolar disorder: decoding contradictory evidence and opinion. Harv Rev Psychiatry 2008; 16(3): 205-209.
304. Xenitidis K, Campbell C, Eppel AB. Antidepressants in rapidcycling bipolar disorder. Br J Psychiatry 2013; 203(1): 75.
305. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160(7): 1252-1262.
306. Hirschfeld RM. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry 2012; 73 Suppl 1: 5-9.
307. McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE. Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor. Int J Neuropsychopharmacol 2014; 17(8): 1315-20.
308. Huang X, Mao YS, Li C, Wang H, Ji JL. Venlafaxine inhibits apoptosis of hippocampal neurons by up-regulating brain-derived neurotrophic factor in a rat depression model. Pharmazie 2014; 69(12): 909-16.
309. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7(4): 243-50.
310. Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45(8): 995-1004.
311. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199-211.
312. Barbosa IG, Rocha NP, Miranda AS, et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr 2013; 35(1): 67-9.
313. Yoo DY, Nam SM, Kim W, et al. N-acetylserotonin increases cell proliferation and differentiating neuroblasts with tertiary dendrites through upregulation of brain-derived neurotrophic factor in the mouse dentate gyrus. J Vet Med Sci 2011; 73(11): 1411-6.
314. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004; 36(2): 243-77.
315. Young IM, Leone RM, Francis P, Stovell P, Silman RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60(1): 114-9.
316. Ganguly S, Weller JL, Ho A, Chemineau P, Malpaux B, Klein DC. Melatonin synthesis: 14-3-3-dependent activation and inhibition of arylalkylamine N-acetyltransferase mediated by phosphoserine-205. Proc Natl Acad Sci USA 2005; 102(4): 1222-7.
317. Lee SY, Choi BH, Hur EM, et al. Norepinephrine activates storeoperated Ca2+ entry coupled to large-conductance Ca2+-activated K+ channels in rat pinealocytes. Am J Physiol Cell Physiol 2006; 290(4): C1060-6.
318. Ishio S, Yamada H, Craft CM, Moriyama Y. Hydroxyindole-Omethyltransferase is another target for L-glutamate-evoked inhibition of melatonin synthesis in rat pinealocytes. Brain Res 1999; 850(1-2): 73-8.
319. Ehrlich A, Schubert F, Pehrs C, Gallinat J. Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder. Psychiatry Res 2015; 233(2): 73-80.
320. Berridge MJ. Calcium signalling remodelling and disease. Biochem Soc Trans 2012; 40(2): 297-309.
321. Tanida T, Tasaka K, Akahoshi E, et al. Fetal exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin transactivates aryl hydrocarbon receptor-responsive element III in the tyrosine hydroxylase immunoreactive neurons of the mouse midbrain. J Appl Toxicol 2014; 34(2): 117-26.
322. Barrot M. The ventral tegmentum and dopamine: A new wave of diversity. Neuroscience 2014; 282C: 243-247.
323. van Enkhuizen J, Milienne-Petiot M, Geyer MA, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology (Berl) 2015; 232(18): 3455-67.
324. Huang M, Felix AR, Flood DG, et al. The novel 7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl) 2014; 231(23): 4541-51.
325. Bortz DM, Mikkelsen JD, Bruno JP. Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience 2013; 255: 55-67.
326. van Enkhuizen J, Janowsky DS, Olivier B, et al. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol 2015; 753: 114-26.
327. Wang LJ, Lee SY, Chen SL, et al. A potential interaction between COMT and MTHFR genetic variants in Han Chinese patients with bipolar II disorder. Sci Rep 2015; 5: 8813.
328. Huang CC, Lu RB, Yen CH, et al. Dopamine transporter gene may be associated with bipolar disorder and its personality traits. Eur Arch Psychiatry Clin Neurosci 2015; 265(4): 281-90.
329. Young AH. The effects of HPA axis function on cognition and its implications for the pathophysiology of bipolar disorder. Harv Rev Psychiatry 2014; 22(6): 331-3.
330. Maier F, Merkl J, Ellereit AL, et al. Hypomania and mania related to dopamine replacement therapy in Parkinson's disease. Parkinsonism Relat Disord 2014; 20(4): 421-7.
331. Takahashi H, Yamada M, Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. J Cereb Blood Flow Metab 2012; 32(7): 1248-58.
332. Marowsky A, Yanagawa Y, Obata K, Vogt KE. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron 2005; 48(6): 1025-37.
333. Favre P, Polosan M, Pichat C, Bougerol T, Baciu M. Cerebral Correlates of Abnormal Emotion Conflict Processing in Euthymic Bipolar Patients: A Functional MRI Study. PLoS One 2015; 10(8): e0134961.
334. Li M, Huang C, Deng W, et al. Contrasting and convergent patterns of amygdala connectivity in mania and depression: a restingstate study. J Affect Disord 2015 173: 53-8.
335. Zhao L, Lin Y, Lao G, et al. Association study of dopamine receptor genes polymorphism with cognitive functions in bipolar I disorder patients. J Affect Disord 2015; 170: 85-90.
336. Yao J, Pan Y, Ding M, Pang H, Wang B. Meta-analysis shows dopamine receptor D1 gene polymorphism is associated with bipolar disorder but not with schizophrenia. Psychiatry Res 2013; 210(3): 1324-5.
337. Johnston CE, Herschel DJ, Lasek AW, Hammer RP Jr, Nikulina EM. Knockdown of ventral tegmental area mu-opioid receptors in rats prevents effects of social defeat stress: implications for amphetamine cross-sensitization, social avoidance, weight regulation and expression of brain-derived neurotrophic factor. Neuropharmacology 2015; 89: 325-34.
338. Peciña M, Martínez-Jauand M, Love T, et al. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J Neurosci 2014; 34(17): 5874-81.
339. McGinty VB, Grace AA. Activity-dependent depression of medial prefrontal cortex inputs to accumbens neurons by the basolateral amygdala. Neuroscience 2009; 162(4): 1429-36.
340. Gill KM, Grace AA. Differential effects of acute and repeated stress on hippocampus and amygdala inputs to the nucleus accumbens shell. Int J Neuropsychopharmacol 2013; 16(9): 2013-25.
341. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton) 2012; 17(8): 733-8.
342. Chen TY, Lee MY, Chen HY, et al. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res 2006; 40(3): 242-50.
343. Vodika M, Ergang P, Mikulecká A, et al. Regulation of 11+-hydroxysteroid dehydrogenase type 1 and 7-hydroxylase CYP7B1 during social stress. PLoS One 2014; 9(2): e89421.
344. Xia MZ, Liang YL, Wang H, et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88-and TRIFdependent signaling pathways in lipopolysaccharide-stimulated RAW264. 7 cells. J Pineal Res 2012; 53(4): 325-34.
345. Ding K, Wang H, Xu J, Lu X, Zhang L, Zhu L. Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway. Neurochem Int 2014; 76: 23-31.
346. Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014; 63(8): 1293-9.
347. Swanson GR, Gorenz A, Shaikh M, et al. Decreased melatonin secretion is associated with increased intestinal permeability and marker of endotoxemia in alcoholics. Am J Physiol Gastrointest Liver Physiol 2015; 308(12): G1004-11.
348. Leclercq S, De Saeger C, Delzenne N, de Timary P, Stärkel P. Role of inflammatory pathways, blood mononuclear cells, and gutderived bacterial products in alcohol dependence. Biol Psychiatry 2014; 76(9): 725-33.
349. Zhou R, Gray NA, Yuan P, et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005; 25(18): 4493-502.
350. Schmidt U, Wochnik GM, Rosenhagen MC, et al. Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor. J Biol Chem 2003; 278(7): 4926-31.
351. Nanavati D, Austin DR, Catapano LA, et al. The effects of chronic treatment with mood stabilizers on the rat hippocampal postsynaptic density proteome. J Neurochem 2011; 119(3): 617-29.
352. Sarıçiçek A, Yalın N, Hıdırólu C, et al. Neuroanatomical correlates of genetic risk for bipolar disorder: A voxel-based morphometry study in bipolar type I patients and healthy first degree relatives. J Affect Disord 2015; 186: 110-8.
353. Johnson CP, Follmer RL, Oguz I, et al. Quantitative T1+ mapping links the cerebellum and lithium use in bipolar disorder. Mol Psychiatry 2015; 20(2): 149.
354. Redlich R, Almeida JJ, Grotegerd D, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression. A voxel-based morphometry-pattern classification approach. JAMA Psychiatry 2014; 71(11): 1222-30.
355. Kim D, Cho HB, Dager SR, et al. Posterior cerebellar vermal deficits in bipolar disorder. J Affect Disord 2013; 150(2): 499-506.
356. Minichino A, Bersani FS, Spagnoli F, et al. Prefronto-cerebellar transcranial direct current stimulation improves sleep quality in euthymic bipolar patients: a brief report. Behav Neurol 2014; 2014: 876521.
357. Chrobak AA, Siwek GP, Siuda-Krzywicka K, et al. Neurological and cerebellar soft signs do not discriminate schizophrenia from bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2015; 64: 96-101.
358. Phillips JR, Hewedi DH, Eissa AM, Moustafa AA. The cerebellum and psychiatric disorders. Front Public Health 2015; 3: 66.
359. Chrobak AA, Siuda-Krzywicka K, Siwek GP, et al. Implicit motor learning in bipolar disorder. J Affect Disord 2015; 174: 250-6.
360. Peterburs J, Cheng DT, Desmond JE. The Association Between Eye Movements and Cerebellar Activation in a Verbal Working Memory Task. Cereb Cortex; In press.
361. Grossauer S, Koeck K, Kau T, Weber J, Vince GH. Behavioral disorders and cognitive impairment associated with cerebellar lesions. J Mol Psychiatry 2015; 3(1): 5.
362. Lupo M, Troisi E, Chiricozzi FR, Clausi S, Molinari M, Leggio M. Inability to Process Negative Emotions in Cerebellar Damage: a Functional Transcranial Doppler Sonographic Study. Cerebellum 2015; 14(6): 663-9.
363. Magal A, Mintz M. Inhibition of the amygdala central nucleus by stimulation of cerebellar output in rats: a putative mechanism for extinction of the conditioned fear response. Eur J Neurosci 2014; 40(10): 3548-55.
364. Pinato L, da Silveira Cruz-Machado S, Franco DG, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct 2015; 220(2): 827-40.
365. Lippai D, Bala S, Petrasek J, et al. Alcohol-induced IL-1+ in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol 2013; 94(1): 171-82.
366. Prestori F, Bonardi C, Mapelli L, et al. Gating of long-term potentiation by nicotinic acetylcholine receptors at the cerebellum input stage. PLoS One 2013; 8(5): e64828.
367. Wu W, Nicolazzo JA, Wen L, et al. Expression of tryptophan 2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One 2013; 8(4): e59749.
368. Taguchi A, Niwa M, Hoshi M, et al. Indoleamine 2, 3-dioxygenase 1 is upregulated in activated microglia in mice cerebellum during acute viral encephalitis. Neurosci Lett 2014; 564: 120-5.
369. Müller DJ, Zai CC, Shinkai T, Strauss J, Kennedy JL. Association between the DAOA/G72 gene and bipolar disorder and metaanalyses in bipolar disorder and schizophrenia. Bipolar Disord 2011; 13(2): 198-207.
370. Sánchez-Martín FJ, Fernández-Salguero PM, Merino JM. Aryl hydrocarbon receptor-dependent induction of apoptosis by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in cerebellar granule cells from mouse. J Neurochem 2011; 118(1): 153-62.
371. Zhu L, Sacco T, Strata P, Sacchetti B. Basolateral amygdala inactivation impairs learning-induced long-term potentiation in the cerebellar cortex. PLoS One 2011; 6(1): e16673.
372. Willemsen LE, Koetsier MA, Balvers M, Beermann C, Stahl B, van Tol EA. Polyunsaturated fatty acids support epithelial barrier integrity and reduce IL-4 mediated permeability in vitro. Eur J Nutr 2008; 47(4): 183-91.
373. Anderson G, Maes M. Melatonin: a natural homeostatic regulator-interactions with immune inflammation and trytophan catabolite pathways in the modulation of migraine and endometriosis. J Nat Prod Res Updates 2015; 1: 7-17.